Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XAIR Stock Forecast 2026-2027
$0.45
Current Price
$4.69M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to XAIR Price Targets
+3,044.7%
To High Target of $14.00
+2,146.2%
To Median Target of $10.00
+349.2%
To Low Target of $2.00
XAIR Price Momentum
-43.0%
1 Week Change
-44.4%
1 Month Change
-90.6%
1 Year Change
-38.4%
Year-to-Date Change
-92.4%
From 52W High of $5.84
+3.5%
From 52W Low of $0.43
📊 TOP ANALYST CALLS
Did XAIR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Beyond Air is one of their latest high-conviction picks.
Latest XAIR Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, XAIR has a bullish consensus with a median price target of $10.00 (ranging from $2.00 to $14.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $0.45, the median forecast implies a 2,146.2% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gregory Fraser at Truist Securities, projecting a 3,044.7% upside. Conversely, the most conservative target is provided by Jason White at Roth MKM, suggesting a 349.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XAIR Analyst Ratings
3
Buy
1
Hold
0
Sell
XAIR Price Target Range
Low
$2.00
Average
$10.00
High
$14.00
Current: $0.45
Latest XAIR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XAIR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 27, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Mar 18, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Mar 10, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Jan 21, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $11.00 |
| Nov 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $11.00 |
| Aug 21, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $11.00 |
| Aug 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $11.00 |
| Jul 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $11.00 |
| Aug 16, 2024 | Roth MKM | Jason White | Buy | Reinstates | $2.00 |
| Aug 7, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $1.00 |
| Jun 25, 2024 | BTIG | Marie Thibault | Neutral | Downgrade | $N/A |
| Jun 25, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $3.50 |
| Apr 30, 2024 | Truist Securities | Gregory Fraser | Buy | Maintains | $8.00 |
| Nov 14, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $10.00 |
| Jul 28, 2023 | Piper Sandler | Jason Bednar | Overweight | Initiates | $10.00 |
| Jul 21, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $14.00 |
| Jun 23, 2023 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $10.00 |
| Jun 15, 2023 | BTIG | Buy | Initiates | $N/A | |
| Jun 29, 2022 | Ladenburg Thalmann | Matthew Kaplan | Buy | Maintains | $23.00 |
| Jun 29, 2022 | Truist Securities | Gregory Fraser | Buy | Maintains | $20.00 |
Beyond Air, Inc. (XAIR) Competitors
The following stocks are similar to Beyond Air based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Beyond Air, Inc. (XAIR) Financial Data
Beyond Air, Inc. has a market capitalization of $4.69M with a P/E ratio of 0.0x. The company generates $6.92M in trailing twelve-month revenue with a -44.9% profit margin.
Revenue growth is +104.7% quarter-over-quarter, while maintaining an operating margin of -300.6% and return on equity of -240.2%.
Valuation Metrics
Market Cap
$4.69M
Enterprise Value
$17.41M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+104.7%
Gross Margin
+13.7%
Operating Margin
-300.6%
Net Margin
-44.9%
EPS Growth
+104.7%
Financial Health
Cash/Price Ratio
+248.7%
Current Ratio
5.1x
Debt/Equity
284.7x
ROE
-240.2%
ROA
-51.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Beyond Air, Inc. (XAIR) Business Model
About Beyond Air, Inc.
What They Do
Specializes in nitric oxide therapy solutions.
Business Model
Beyond Air, Inc. operates as a clinical-stage medical device and biopharmaceutical company, generating revenue through the sale of its LungFit platform and related therapeutic products. This includes innovative nitric oxide generators that provide on-demand treatments for various respiratory and neurological conditions, allowing the company to tap into both hospital and home healthcare markets.
Additional Information
The company’s product offerings target serious health conditions such as pulmonary hypertension in newborns, viral lung infections, and nontuberculous mycobacteria infections. Beyond Air is positioned to advance treatment options with its patented technologies and has a leadership team experienced in clinical and scientific fields, indicating a strong potential for growth and impact in healthcare.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
61
CEO
Mr. Robert Scott Goodman
Country
United States
IPO Year
2018
Website
www.beyondair.netBeyond Air, Inc. (XAIR) Latest News & Analysis
Latest News
Quick Summary
Beyond Air, Inc. (NASDAQ: XAIR) will participate in the D. Boral Capital Global Conference on May 7, 2026, featuring CEO Robert Goodman and CFO Dan Moorhead.
Why It Matters
Management participation in a prominent conference can boost investor confidence, enhance visibility, and potentially lead to new partnerships or funding opportunities for Beyond Air, Inc.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Data for the 2026 AACR Annual Meeting will be presented on April 19th, as listed in the Online Itinerary Planner.
Why It Matters
The upcoming presentation at the AACR Annual Meeting could impact biotech stocks and research funding, influencing market sentiment and investment decisions in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Beyond Air, Inc. (NASDAQ: XAIR) announced an independent review highlighting high-dose inhaled nitric oxide's potential as an antimicrobial therapy for respiratory infections, published in Intensive Care Medicine Experimental.
Why It Matters
The publication highlights Beyond Air's potential breakthrough in antimicrobial therapy, which may drive investor interest and stock performance due to its innovative approach and market implications.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Beyond Air, Inc. (XAIR) held its Q3 2026 earnings call, providing updates on financial performance and business developments. Further details can be found in the complete transcript.
Why It Matters
The Q3 2026 earnings call for Beyond Air, Inc. provides crucial insights into the company's financial health, growth prospects, and market strategies, directly impacting stock performance and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
2 months ago
Quick Summary
Beyond Air reported a 105% YoY revenue increase to $2.2 million in Q3, maintaining 2026 revenue guidance of $8-10 million. They signed a LOI for XTL Biopharmaceuticals to acquire 85% of NeuroNOS, with potential proceeds of $32.5 million.
Why It Matters
Revenue growth of 105% signals strong performance. The acquisition deal may enhance value, while robust cash reserves support future operations. Positive momentum ahead of key data presentation is promising.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Beyond Air, Inc. (NASDAQ: XAIR) will have CEO Steve Lisi participate in the BTIG MedTech Conference on Feb 9-11 and the Noble Capital Markets Conference on Feb 4-5, 2026.
Why It Matters
Beyond Air's CEO participation in key conferences highlights the company's visibility and potential growth in the medical sector, which could influence investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XAIR Stock
What is Beyond Air, Inc.'s (XAIR) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Beyond Air, Inc. (XAIR) has a median price target of $10.00. The highest price target is $14.00 and the lowest is $2.00.
Is XAIR stock a good investment in 2026?
According to current analyst ratings, XAIR has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XAIR stock?
Wall Street analysts predict XAIR stock could reach $10.00 in the next 12 months. This represents a 2,146.2% increase from the current price of $0.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Beyond Air, Inc.'s business model?
Beyond Air, Inc. operates as a clinical-stage medical device and biopharmaceutical company, generating revenue through the sale of its LungFit platform and related therapeutic products. This includes innovative nitric oxide generators that provide on-demand treatments for various respiratory and neurological conditions, allowing the company to tap into both hospital and home healthcare markets.
What is the highest forecasted price for XAIR Beyond Air, Inc.?
The highest price target for XAIR is $14.00 from Gregory Fraser at Truist Securities, which represents a 3,044.7% increase from the current price of $0.45.
What is the lowest forecasted price for XAIR Beyond Air, Inc.?
The lowest price target for XAIR is $2.00 from Jason White at Roth MKM, which represents a 349.2% increase from the current price of $0.45.
What is the overall XAIR consensus from analysts for Beyond Air, Inc.?
The overall analyst consensus for XAIR is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are XAIR stock price projections?
Stock price projections, including those for Beyond Air, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 4:17 AM UTC